Diana Hausman
Diana Hausman's purchase track record
Diana Hausman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/2/2025 | IMRX | $20K | +77.2% | +83.3% | +9.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Transaction History
| IMRX | ▲ Buy | Open Market | 2,500 | $9K | 7/2/2025 | View on chart |
| IMRX | ▲ Buy | Open Market | 3,000 | $11K | 7/2/2025 | View on chart |
| ZNTL | ▼ Sell | Open Market | 3,356 | $42K | 5/9/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 337,500 | $0 | 2/1/2024 | View on chart |
| ZNTL | ▲ Buy | Grant | 39,732 | $0 | 5/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026
Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.